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Suppl. Material and Methods
The study was designed and conducted according to the reporting recommendations for Tumor Marker Diagnostic Studies (REMARK) guidelines [[1] ]. A total of 914 patients with pancreatic cancer, chronic pancreatitis, liver cirrhosis, healthy blood donors and preoperative patients with non-pancreatic or liver disease were prospectively enrolled in the study. All patients gave their written informed consent and the local ethics review boards approved the protocol at all three participating centers (Az. 110/99). Patients were consecutively recruited from University referral centers in Greifswald (80 pancreatic cancer patients, 120 chronic pancreatitis patients, 100 liver cirrhosis patients and 117 blood donors), Kiel (34 pancreatic cancer patients, 2 chronic pancreatitis patients, and 64 blood donors) and Dresden (157 pancreatic cancer patients, 160 chronic pancreatitis patients, and 80 controls (non-pancreatic disease). The non-pancreatic controls had the following patients' characteristics: all controls underwent general anaesthesia.
The cohort comprised 52.2% male subjects, mean age was 64 years ± 14.4 SD, 22.5% were diabetics and mean BMI was calculated with 26.8 ± 4.8 SD. 20 patients underwent vascular surgery, 18 patients received a hernia repair, 3 were resected for goiter and 39 received various other small surgical procedures under general anaesthesia. None was operated in metabolically deranged state. The final diagnosis of pancreatic cancer was established by a pathologist based on histology examination (either on resection specimen, on pancreatic fine needle aspiration or biopsy of liver metastasis) and PDAC ruled out in the disease groups by a medium follow up time of 24 months. EDTA-blood samples were taken before cancer treatment. For pancreatitis patients inclusion criteria for all cohorts included written informed consent given by patients and preexisting chronic pancreatitis. The diagnosis of chronic pancreatitis was made if one or more of the following criteria were met and no other diagnosis was more likely [2] : recurrent bouts of pancreatic pain with documented rise in amylase or lipase activity for a duration of more than one year and radiological evidence supporting the diagnosis, pancreatic calcifications, histological proof of chronic pancreatitis, unequivocal changes in pancreatic duct morphology, severely abnormal pancreatic function tests with maldigestion. Calcifications were identified on CT-scan, diabetes was diagnosed as suggested by the WHO definition and exocrine insufficiency was determined by either fecal elastase measurement or concurrent pancreatic enzyme supplementation. Suppl. table 7 gives a detailed summary on the patients' characteristics of our cohort.
Plasma was prepared by centrifugation at 1500 x g for 15 min at 4 to 8°C. The plasma supernatant was removed, mixed in a new centrifugation tube by inverting, split into 0.5-ml aliquots and stored at -80°C in 2-ml screw cap tubes. Samples were shipped on dry ice to the analytical laboratory. Serum sampling was performed according to the protocol above except BD Before analysis of the test set metabolites and algorithms were defined. Power analysis was performed to estimate an adequate sample size using representative metabolite profiling standard deviations that were determined in earlier studies [4] . The primary aim of the study was 
The lipid classes monoacylglycerides (MAG), triacylglycerides (TAG), phosphatidylcholines (PC), phosphatidylserines (PS), phosphatidylinositoles (PI), lysophosphatidylcholines (LPC), diacylglycerides (DAG), free fatty acids (FFA) were measured by GC-FID (Flame Ionization
Detector). The fractions were analyzed by GC-FID after derivatization with TMSH (Trimethyl sulfonium hydroxide), yielding the fatty acid methyl esters (FAME) corresponding to the acyl moieties of the class-separated lipids. The concentrations of FAME from C14 to C24 were determined in each fraction.
Data normalization, data set alignment, metabolite levels and nomenclature
Metabolite profiling based on a semi-quantitative analytical platform results in relative metabolite levels ("ratio") to a defined reference. To support this concept and to allow an alignment of different analytical batches, two different reference sample types were run in parallel throughout the whole process. First, a project pool was generated from aliquots of all samples and measured with four replicates within each analytical sequence that comprised 24 samples. For Second, to allow for an experiment-to-experiment alignment of semi-quantitative data, MxPool™
(a large pool of a commercial human EDTA plasma suited for alignment of MxP ® studies) was analyzed with 12 replicated samples in the identification and validation studies, but not in the exploratory study and the pool-normalized ratios were further normalized to the median of the MxPool™ samples, i.e. ratios from this study are on the same level and therefore comparable with data from other studies normalized to other aliquots of the same MxPool™.
The limit of detection and the dynamic range of the semi-quantitative measurements were determined by dilution and spiking experiments during method development. The term "additional" (add.) was applied to metabolite names when the quantification may be influenced by metabolites exhibiting identical analytical characteristics with respect to the quantitation method. A rigorous quality control was performed on peak, analyte and sample level and has been described previously [10] .
We were only willing to proceed from the training to the test study if in the training study absolute performance of our biomarker signature alone or in combination with CA19-9 would either show diagnostic improvement of greater 10% in comparison to CA19-9 or Sensitivity be > 80% and Specificity: ≥ 85% [+/-range of 95% CI] or AROC: ≥ 0.85.
Metabolite identification was carried out by authentic standards where applicable. In case the authentic standard is not commercially available, in-depth MS-experiments were carried out and interpreted resulting into a highly reliable structure annotation from our scientific knowledge.
Such experiments include determination of exact mass by fourier transform ion cyclotron resonance mass spectrometry (FT-ICR MS), labeling experiments, changes in derivatization or ionization-modes.
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Definition of high priority metabolites: High priority metabolites are all metabolites semi quantitatively detected above the limit of quantification for the majority of analyzed samples.
Semi-quantitative ratios are peak data normalized to median of pooled samples within each analytical sequence in order to correct for device variability (=> ratios relative to pool). The pool was generated from aliquots of each sample. Samples of the training and test data set were analyzed in two batches including MxPool™. For the linking of semi-quantitative data a second normalization step was introduced by further normalizing pool-normalized data to median of MxPool™ within each analytical batch. Total quantified data remained in absolute concentrations during batch alignment. Suppl. A simple linear model (ANOVA, package nlme) with "disease", "age", "body mass index", "sex"
and "sample storage time" as fixed effects was fitted to the data. Significance level was set to 5%. The multiple test problem was addressed by calculating the false discovery rate (FDR) using the Benjamini & Hochberg method [[11] ].
To classify patients depending on their metabolic profiles a penalized logistic regression was fitted via using the Elastic Net Algorithm using the R package glmnet [[12] ]. Equal penalties were used for both the L1 and the L2 norm. The performance as measured by the sensitivity at a fixed specificity of 85% was determined on the training data by tenfold cross-validation. This corresponded to a cutoff of 0.384. Afterwards the cutoff was applied without retraining on the test data and the performance measured in terms of sensitivity and specificity.
Confidence levels for the AUC and the specificity at a fixed sensitivity were calculated using the binormal model for the ROC Curve. When the sensitivity is fixed at a particular value PPV, NPV and accuracy become monotone functions of the specificity and confidence intervals for these estimates are obtained by transformation of the confidence interval for the specificity.
Confidence intervals for sensitivity, specificity and accuracy were obtained for the pre-specified cutoff in the training data by the method of Clopper and Pearson for the binomial distribution. For PPV and NPV the confidence intervals were obtained by the method of Gart and Nam [ [13] ] for
